Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune (ALT – Research Report) on February 28 and set a price target of $25.00.

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based ...

Fintel reports that on February 28, 2025, William Blair initiated coverage of Altimmune (NasdaqGM:ALT) with a Market Perform ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two ...

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on ...

EST Altimmune (ALT) files $400M mixed securities shelfDiscover the Best Stocks and Maximize Your Portfolio: See what stocks are receiving ...

Altimmune (NASDAQ:ALT) Inc. reported its fourth-quarter 2024 earnings, revealing a slight beat on EPS forecasts with an actual EPS of -0.33 compared to the forecasted -0.34. Revenue, however ...

Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are currently covering the stock, MarketBeat reports. One equities research ...